FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week ...

Participants achieved an average weight loss of 20.2% with Zepbound ... However, the study was not powered to compare the safety and tolerability of Zepbound and the safety and tolerability ...

Injectable GLP-1 receptor agonist drugs Wegovy (semaglutide) and Zepbound (tirzepatide ... first to undertake a head-to-head comparison of the weight loss effectiveness of semaglutide and ...

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on Wegovy.

Women typically lose more weight on Zepbound and Wegovy than men do ... want to consider detailed results on how the two medicines compare across different types of patients before making ...